Energenesis Biomedical Co (TPE:6657) EBIT: NT$-257.94 Mil (TTM As of Dec. 2025)


TPE:6657 Energenesis Biomedical Co Ltd TPE:6657
64 GF Score
Price NT$34.90
GF Value NT$51.28
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Energenesis Biomedical Co EBIT?

Energenesis Biomedical Co TPE:6657 -2.92% 64 EBIT is NT$-257.94 Mil as of Dec. 2025. GuruFocus rates TPE:6657 with a GF Score™ of 64/100 and a GF Value™ of NT$51.28 (Possible Value Trap). The stock has 3 warning signs investors should review.

Energenesis Biomedical Co's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was NT$-64.67 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-257.94 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Energenesis Biomedical Co's annualized ROC % for the quarter that ended in Dec. 2025 was -298.08%. Energenesis Biomedical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -321.61%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Energenesis Biomedical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -11.49%.


Energenesis Biomedical Co  (TPE:6657) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Energenesis Biomedical Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-277.652 * ( 1 - 0% )/( (95.925 + 90.367)/ 2 )
=-277.652/93.146
=-298.08 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=948.982 - 37.606 - ( 838.102 - max(0, 43.422 - 864.431+838.102))
=90.367

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Energenesis Biomedical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-258.664/( ( (80.418 + max(1.723, 0)) + (78.715 + max(-12.025, 0)) )/ 2 )
=-258.664/( ( 82.141 + 78.715 )/ 2 )
=-258.664/80.428
=-321.61 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.928 + 0.853 + 21.421) - (21.097 + 0 + 0.382)
=1.723

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.394 + 0.864 + 23.587) - (37.606 + 0 + 0.264)
=-12.025

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Energenesis Biomedical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-257.939/2244.726
=-11.49 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Energenesis Biomedical Co EBIT Related Terms


Energenesis Biomedical Co EBIT Historical Data

* Premium members only.

The historical data trend for Energenesis Biomedical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Energenesis Biomedical Co EBIT Chart

Energenesis Biomedical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -119.95 -265.46 -260.17 -230.87 -257.94

Energenesis Biomedical Co Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -49.85 -96.87 -47.53 -48.88 -64.67

TPE:6657 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Energenesis Biomedical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Energenesis Biomedical Co EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Energenesis Biomedical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Energenesis Biomedical Co's EV-to-EBIT falls into.


TPE:6657
64GF Score
Energenesis Biomedical Co Ltd TPE:6657
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Energenesis Biomedical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-257.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$-257.94 Mil mean?
Energenesis Biomedical Co (TPE:6657) has a EBIT of NT$-257.94 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Energenesis Biomedical Co.
Is Energenesis Biomedical Co's EBIT too high?
Energenesis Biomedical Co's current EBIT is NT$-257.94 Mil. Overall, Energenesis Biomedical Co has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Energenesis Biomedical Co's EBIT compare to VRTX and REGN?
Energenesis Biomedical Co's EBIT of NT$-257.94 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Energenesis Biomedical Co. Energenesis Biomedical Co's current EBIT is NT$-257.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Energenesis Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Energenesis Biomedical Co (TPE:6657) is currently considered Possible Value Trap. The stock's GF Value™ is NT$51.28, compared to a current price of NT$34.90 — trading 31.9% below its estimated fair value. The current EBIT is NT$-257.94 Mil. Energenesis Biomedical Co's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Energenesis Biomedical Co (TPE:6657), the current EBIT is NT$-257.94 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Energenesis Biomedical Co (TPE:6657) Overvalued in 2026?

Based on GuruFocus' analysis, Energenesis Biomedical Co stock appears to be undervalued. The current stock price of NT$34.90 is trading 31.9% below its estimated GF Value™ of NT$51.28. GuruFocus considers Energenesis Biomedical Co to be Possible Value Trap.

Key valuation signals for TPE:6657:

  • EBIT: NT$-257.94 Mil
  • GF Value™: NT$51.28 vs. price of NT$34.90 (31.9% below fair value)
  • GF Score™: 64/100 with 3 warning signs

No single metric tells the full story. See the TPE:6657 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Energenesis Biomedical Co Business Description

Address No. 21, Lane 583, Ruiguang Road, 6th Floor -3, Neihu District, Taipei, TWN, 11492
Energenesis Biomedical Co Ltd is a biomedicine company. The company is engaged in businesses related to biological experimentation and analysis, as well as new drugs development. The company uses its ENERGI drug development platform to activate AMP-activated protein kinase (AMPK), a key enzyme in cell energy regulation, as a means of developing disease treatments. The product pipeline of the company consists of ENERGI-F703, a diabetic foot ulcers treatment gel; ENERGI-F701, a product developed for male hair loss; ENERGI-F704, an inflammatory bowel disease treatment; and ENERGI-F711, a burn cream,F708, Asthama treatment, and others.
64GF Score

Get the complete analysis for TPE:6657

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$34.90
Price
NT$51.28
GF Value